Ancrod may not provide clinical benefit to patients with acute ischaemic stroke

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1566, 2006-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Potential of Intra-Arterial Thrombolytic Therapy in Patients with Acute Ischaemic Stroke

By Xavier A.R.

CNS Drugs, Vol. 17, Iss. 4, 2003-01 ,pp. : 213-224

Adis International

Access to resources Recommend Favorite

Sulfonylureas may be associated with beneficial outcomes in patients with type II diabetes mellitus who experience an acute ischaemic stroke

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Aspirin and Heparin in Acute Ischaemic Stroke in Older Patients

By Gubitz G.J. Sandercock P.A.G.

Drugs & Aging, Vol. 15, Iss. 1, 1999-07 ,pp. : 29-36

Adis International

Access to resources Recommend Favorite

Pardoprunox monotherapy may provide benefit for patients with early-stage Parkinson's disease

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Zoledronic acid may provide a structural benefit in patients with early rheumatoid arthritis

Inpharma, Vol. 1, Iss. 1542, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite